The HHS Office of Inspector General launched an investigation in response to a conflict-of-interest complaint by Amphastar Pharmaceuticals against Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research. The issue involves a scientific paper written by Woodcock and scientists at Momenta Pharmaceuticals while Amphastar and Momenta were awaiting FDA approval for competing versions of blood thinner Lovenox.

Related Summaries